NCT07154706 2026-04-14
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.
Phase 3 Recruiting
Clinical Trials
3 trialsNCT06564324 2026-04-13
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc.
Phase 3 Recruiting
NCT07008287 2025-07-22
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
Innovent Biologics (Suzhou) Co. Ltd.
Recruiting